Omada Health, Inc.
OMDA Nasdaq· Services-Health Services
Last close · Oct 26, 2026
$19.24
KIRA · Stoqly’s AI analyst, in plain words
- Omada Health, Inc. had $260M of revenue in fiscal 2025, up 53.2% on the year before.
- Its operating margin was −4.6%, up 21.1 pts: of every 100 in sales, about −5 is left after running the business.
- Omada Health, Inc. lost $12.8M in fiscal 2025.
- Free cash flow was $16.9M in fiscal 2025, 6.5% of revenue.
- Omada Health, Inc. has $222M more cash than debt.
Market cap
$1.2B
P/E
18.0x
Revenue
$260M
Net income
−$12.8M
Free cash flow
$16.9M
Operating margin
−4.6%
Omada Health, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+53.2%
Yes. Sales grew 53.2% last year.
Does it make a profit?
−4.9%
No. It lost money last year.
Does profit turn into cash?
6.5%
Partly. 6.5% of sales ends up as free cash.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
18.0x
One share costs 18.0 times its yearly profit per share.
What Omada Health, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 6, 2026
- Legal name
- Omada Health, Inc.
- CIK
- 0001611115
Omada Health, Inc. · OMDA
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $123M | $170M | $260M |
| Revenue growth | — | 38.3% | 53.2% |
| Gross margin | 57.0% | 60.6% | 65.7% |
| Operating margin | −53.8% | −25.7% | −4.6% |
| Net income | −$67.5M | −$47.1M | −$12.8M |
| Net margin | −55.0% | −27.8% | −4.9% |
| Diluted EPS | −$9.52 | −$6.11 | −$0.35 |
| Cash | |||
| Cash from operations | −$49.7M | −$34.2M | $18.3M |
| Capital expenditure | $0.4M | $0.6M | $1.3M |
| Free cash flow | −$50.2M | −$34.8M | $16.9M |
| FCF margin | −40.8% | −20.5% | 6.5% |
| Share count change | — | 8.9% | 374.5% |
| Debt and strength | |||
| Cash and short-term investments | $116M | $76.4M | $222M |
| Debt incl. finance leases | — | $29.8M | $0.0M |
| Shareholders' equity | −$350M | −$384M | $230M |
| Current ratio | — | 2.1x | 3.6x |
| Interest coverage | −14.0x | −9.7x | −4.7x |
| Returns and quality | |||
| Return on capital | — | — | −123.7% |
| Return on tangible equity | — | — | −6.0% |
| Piotroski F-score | — | — | 6 |
| Altman Z'' | — | −13.6 | 2.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$12.0M
4 insiders
Of sales under plans
65%
$7.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Omada Health, Inc. · OMDA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $19.24 a share, the company is worth $1.2B: 18.0 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001611115). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.